Wave Life Sciences starts Phase 2a obesity trial for WVE-007 drug

June 24, 2026 8:30 AM

Wave Life Sciences Ltd. (Nasdaq: WVE) announced it has initiated the Phase 2a portion of its INLIGHT clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found